Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects!

We report herein the first such case and believe that further studies confirming this association are warranted. We further review the existing posterior reversible encephalopathy syndrome cases associated with targeted therapies in the scientific literature.

http://opp.sagepub.com/cgi/content/abstract/21/6/443?rss=1

Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Khurana, A., Dasanu, C. A. Tags: Review Articles Source Type: research